Latest & greatest articles for migraine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on migraine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on migraine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for migraine

141. Injection of botulinum toxin (Botox) for prophylaxis of headaches in adults with chronic migraine

Injection of botulinum toxin (Botox) for prophylaxis of headaches in adults with chronic migraine Injection of botulinum toxin (Botox) for prophylaxis of headaches in adults with chronic migraine Injection of botulinum toxin (Botox) for prophylaxis of headaches in adults with chronic migraine Medical Services Advisory Committee Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Medical Services Advisory Committee. Injection of botulinum toxin (Botox) for prophylaxis of headaches in adults with chronic migraine. Canberra: Medical Services Advisory Committee (MSAC). MSAC application 1168. 2012 Authors' conclusions After considering the strength of the available evidence in relation to the safety, clinical effectiveness and cost-effectiveness of injecting botulinum toxin type A (Botox®) in refractory chronic migraine, MSAC supports its public funding via a new

Health Technology Assessment (HTA) Database.2012

142. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine

OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine 21956721 2011 10 11 2012 01 11 2011 10 11 1526-632X 77 15 2011 Oct 11 Neurology Neurology OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. 1465-72 10.1212/WNL.0b013e318232ab65 To assess the effects of treatment with onabotulinumtoxinA (Botox, Allergan, Inc., Irvine, CA) on health-related quality of life (HRQoL) and headache impact in adults with chronic migraine (CM). The Phase (...) III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) clinical program (PREEMPT 1 and 2) included a 24-week, double-blind phase (2 12-week cycles) followed by a 32-week, open-label phase (3 cycles). Thirty-one injections of 5U each (155 U of onabotulinumtoxinA or placebo) were administered to fixed sites. An additional 40 U could be administered "following the pain." Prespecified analysis of headache impact (Headache Impact Test [HIT]-6) and HRQoL (Migraine-Specific Quality

EvidenceUpdates2011

143. Botulinum toxin treatment for migraine headache

Botulinum toxin treatment for migraine headache Botulinum toxin treatment for migraine headache Botulinum toxin treatment for migraine headache Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Botulinum toxin treatment for migraine headache. Lansdale: HAYES, Inc.. Directory Publication. 2011 Authors' objectives Botulinum toxin (BTX), a neurotoxin produced (...) ; Migraine Disorders; Neuromuscular Agents Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32011001451 Date abstract record published 26/10/2011 Health Technology Assessment (HTA) database Copyright © 2011 Winifred S. Hayes, Inc Homepage Options Print

Health Technology Assessment (HTA) Database.2011

144. Steroids for Prevention of Migraine Recurrence

Steroids for Prevention of Migraine Recurrence Steroids for Prevention of Migraine Recurrence – TheNNTTheNNT Steroids (Dexamethasone) for Prevention of Migraine Recurrence 10 for migraine recurrence In Summary, for those with migraines who took the steroids: Benefits in NNT 89.7% saw no benefit 10.3% were helped by preventing migraine recurrence 1 in 10 were helped (migraine recurrence prevented) Harms in NNT An unknown number were harmed by medication effects An unknown number were harmed (...) (medication effects) View As: NNT % Source: Efficacy Endpoints: Recurrence of migraine between 24 and 72 hrs of leaving the Emergency Department Harm Endpoints: Adverse drug events Narrative: Migraine is a common entity and is usually successfully treated in outpatient and inpatient environments. Recurrence of headache within two days following successful termination of migraine is reportedly as high as 50%, and up to 10% of patients treated in emergency departments will return for this ‘rebound’ headache

theNNT2011

145. Metoclopramide for acute migraine: a dose-finding randomized clinical trial

Metoclopramide for acute migraine: a dose-finding randomized clinical trial 21227540 2011 04 25 2011 06 29 2016 10 19 1097-6760 57 5 2011 May Annals of emergency medicine Ann Emerg Med Metoclopramide for acute migraine: a dose-finding randomized clinical trial. 475-82.e1 10.1016/j.annemergmed.2010.11.023 Intravenous metoclopramide is effective as primary therapy for acute migraine, but the optimal dose of this medication is not yet known. The objective of this study is to compare the efficacy (...) and safety of 3 different doses of intravenous metoclopramide for the treatment of acute migraine. This was a randomized, double-blind, dose-finding study conducted on patients who presented to our emergency department (ED) meeting International Classification of Headache Disorders criteria for migraine without aura. We randomized patients to 10, 20, or 40 mg of intravenous metoclopramide. We coadministered diphenhydramine to all patients to prevent extrapyramidal adverse effects. The primary outcome

EvidenceUpdates2011 Full Text: Link to full Text with Trip Pro

146. Frovatriptan as preemptive treatment for fasting-induced migraine

Frovatriptan as preemptive treatment for fasting-induced migraine 21269298 2011 02 28 2011 07 07 2012 11 15 1526-4610 51 3 2011 Mar Headache Headache Frovatriptan as preemptive treatment for fasting-induced migraine. 369-74 10.1111/j.1526-4610.2010.01827.x To examine frovatriptan's efficacy as preemptive treatment for fasting-induced migraine. Fasting is a common migraine trigger that cannot always be avoided. The development of a short-term preemptive approach would be of benefit. Because (...) of its longer half-life, frovatriptan has been effectively used for short-term daily use to prevent menstrually related migraines and might prove useful in the prevention of fasting-induced migraine. This was a double-blind, placebo-controlled, randomized, parallel-group trial. With a history of fasting-induced episodic migraine were randomly assigned to receive either frovatriptan (5.0 mg) or placebo (ratio 1:1). Took a single dose of study medication at the start of their 20-hour fast. Information

EvidenceUpdates2011

148. Headache, migraine, and structural brain lesions and function: population based Epidemiology of Vascular Ageing-MRI study.

Headache, migraine, and structural brain lesions and function: population based Epidemiology of Vascular Ageing-MRI study. OBJECTIVE: To evaluate the association of overall and specific headaches with volume of white matter hyperintensities, brain infarcts, and cognition. DESIGN: Population based, cross sectional study. SETTING: Epidemiology of Vascular Ageing study, Nantes, France. PARTICIPANTS: 780 participants (mean age 69, 58.5% women) with detailed headache assessment. MAIN OUTCOME (...) MEASURES: Brain scans were evaluated for volume of white matter hyperintensities (by fully automated imaging processing) and for classification of infarcts (by visual reading with a standardised assessment grid). Cognitive function was assessed by a battery of tests including the mini-mental state examination. RESULTS: 163 (20.9%) participants reported a history of severe headache and 116 had migraine, of whom 17 (14.7%) reported aura symptoms. An association was found between any history of severe

BMJ2011 Full Text: Link to full Text with Trip Pro

149. Randomised controlled trial: Combined prophylactic ?-blocker and behavioural migraine management improves 30-day migraine outcomes compared with either strategy alone, or optimised acute treatment only

Randomised controlled trial: Combined prophylactic ?-blocker and behavioural migraine management improves 30-day migraine outcomes compared with either strategy alone, or optimised acute treatment only Combined prophylactic β-blocker and behavioural migraine management improves 30-day migraine outcomes compared with either strategy alone, or optimised acute treatment only | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Combined prophylactic β-blocker and behavioural migraine management improves 30-day migraine outcomes compared with either strategy

Evidence-Based Medicine (Requires free registration)2011

150. Diagnostic accuracy of the ID migraine: a systematic review and meta-analysis

Diagnostic accuracy of the ID migraine: a systematic review and meta-analysis Diagnostic accuracy of the ID migraine: a systematic review and meta-analysis Diagnostic accuracy of the ID migraine: a systematic review and meta-analysis Cousins G, Hijazze S, Van de Laar FA, Fahey T CRD summary The review concluded the identification of migraine test was a brief, practical and easy to use diagnostic tool; its application was likely to improve diagnosis and management of migraine. These conclusions (...) are not fully supported by the data; no data were presented on practicality or impact on patient management. Accuracy data indicated that the ability to rule-in migraine was moderate. Authors' objectives To assess the diagnostic accuracy of the identification of migraine test (ID migraine) as a decision rule for diagnosing patients with migraine. Searching PubMed, EMBASE and The Cochrane library were searched to November 2010 with no language restrictions. Search terms were reported and included terms

DARE.2011

151. Cohort study: Migraine with aura ? indication of an increased risk of hemorrhagic stroke in women (Women's Health Study) and increased risk of overall death in an Icelandic population (Reykjavik Study)

Cohort study: Migraine with aura ? indication of an increased risk of hemorrhagic stroke in women (Women's Health Study) and increased risk of overall death in an Icelandic population (Reykjavik Study) Migraine with aura – indication of an increased risk of hemorrhagic stroke in women (Women's Health Study) and increased risk of overall death in an Icelandic population (Reykjavik Study) | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our (...) use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Migraine with aura – indication of an increased risk of hemorrhagic stroke in women (Women's Health Study

Evidence-Based Medicine (Requires free registration)2011

152. Prevention of medication overuse in patients with migraine

Prevention of medication overuse in patients with migraine 20800968 2010 10 15 2011 02 14 2011 08 01 1872-6623 151 2 2010 Nov Pain Pain Prevention of medication overuse in patients with migraine. 404-13 10.1016/j.pain.2010.07.032 This multi-center study compared the therapeutic effect of a cognitive-behavioral minimal contact program (MCT) to the effect of a brochure (bibliotherapy) for the prevention of medication overuse headache (MOH) in migraine patients. Seven German headache centers (...) recruited 182 migraine patients with high triptan or analgesic intake frequency. Patients were randomly allocated to either the MCT-group, receiving both an MCT program and an educational brochure or to the biblio-group receiving only the brochure. All participants continued usual medical treatment. Course of headaches, intake of analgesics or triptans after training, 3 months post-training as well as 1-2 years (mean 15.7 months) later and psychological variables were defined as outcome variables

EvidenceUpdates2011

153. Acupuncture for Treatment of Acute Migraine: A Systematic Review

Acupuncture for Treatment of Acute Migraine: A Systematic Review "Acupuncture for Treatment of Acute Migraine: A Systematic Review" by Virginia R. Whitney < > > > > > Title Author Date of Award Winter 1-2011 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Acute migraine attacks effect 18% of women in the United States, and six to seven percent of men. The disabling nature of these attacks, in combination with their chronic (...) patterns of occurrence, impact and disrupt multiple aspects of a person’s life. There are many abortive medications available, but none are free from side effects. Migraineurs continue to explore alternative treatment options for this continuous battle against acute migraine attacks. This systematic review examines the efficacy of acupuncture for the treatment of an acute migraine attack when compared to a control. The evidence was reviewed and evaluated using GRADE. Method: A comprehensive review

Pacific University EBM Capstone Project2011

154. Riboflavin as Migraine Prophylaxis in Children and Adolescents: A Systematic Review of the Literature

Riboflavin as Migraine Prophylaxis in Children and Adolescents: A Systematic Review of the Literature "Riboflavin as Migraine Prophylaxis in Children and Adolescents: A Syst" by David N. Counts < > > > > > Title Author Date of Award 5-2011 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Torry Cobb, DHSc, MPH, PA-C Rights . Abstract Background: Migraine headache is a common condition among children and the prevalence increases (...) into adolescence. Multiple studies have shown riboflavin to be an effective and safe agent for migraine prophylaxis in adults but few studies have looked at using riboflavin in children and adolescents. The purpose of this paper was to perform a systematic review of the literature on the use of riboflavin for migraine prophylaxis in the pediatric population including children and adolescents. The quality of evidence was evaluated using the Grading of Recommendations Assessment, Development and Evaluation

Pacific University EBM Capstone Project2011

155. Prophylaxis of migraine with melatonin: a randomized controlled trial

Prophylaxis of migraine with melatonin: a randomized controlled trial 20975054 2010 10 26 2010 11 12 2013 11 21 1526-632X 75 17 2010 Oct 26 Neurology Neurology Prophylaxis of migraine with melatonin: a randomized controlled trial. 1527-32 10.1212/WNL.0b013e3181f9618c A previous open-label study of melatonin, a key substance in the circadian system, has shown effects on migraine that warrant a placebo-controlled study. A randomized, double-blind, placebo-controlled crossover study was carried (...) out in 2 centers. Men and women, aged 18-65 years, with migraine but otherwise healthy, experiencing 2-7 attacks per month, were recruited from the general population. After a 4-week run-in phase, 48 subjects were randomized to receive either placebo or extended-release melatonin (Circadin®, Neurim Pharmaceuticals Ltd., Tel Aviv, Israel) at a dose of 2 mg 1 hour before bedtime for 8 weeks. After a 6-week washout treatment was switched. The primary outcome was migraine attack frequency (AF). A

EvidenceUpdates2010

156. A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department

A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department 20045576 2010 07 12 2010 08 05 2014 11 20 1097-6760 56 1 2010 Jul Annals of emergency medicine Ann Emerg Med A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department. 1-6 10.1016/j.annemergmed.2009.11.020 Intravenous (IV) prochlorperazine (...) with diphenhydramine is superior to subcutaneous sumatriptan in the treatment of migraine patients presenting to the emergency department (ED). In this randomized, double-blind, placebo-controlled trial, after providing written informed consent, patients presenting to the ED with a chief complaint of migraine received a 500-mL bolus of IV saline solution and either 10 mg prochlorperazine with 12.5 mg diphenhydramine IV plus saline solution placebo subcutaneously or saline solution placebo IV plus 6 mg sumatriptan

EvidenceUpdates2010

157. Migraine and risk of haemorrhagic stroke in women: prospective cohort study.

Migraine and risk of haemorrhagic stroke in women: prospective cohort study. OBJECTIVES: To examine the association between migraine and migraine aura status with risk of haemorrhagic stroke. DESIGN: Prospective cohort study. SETTING: Women's Health Study, United States. PARTICIPANTS: 27,860 women aged >or=45 who were free from stroke or other major disease at baseline and had provided information on self reported migraine, aura status, and lipid values. MAIN OUTCOME MEASURES: Time to first (...) haemorrhagic stroke and subtypes of haemorrhagic stroke. RESULTS: At baseline, 5130 (18%) women reported any history of migraine; of the 3612 with active migraine (migraine in the previous year), 1435 (40%) described having aura. During a mean of 13.6 years of follow-up, 85 haemorrhagic strokes were confirmed after review of medical records. Compared with women without a history of migraine, there was no increased risk of haemorrhagic stroke in those who reported any history of migraine (adjusted hazard

BMJ2010 Full Text: Link to full Text with Trip Pro

158. Migraine with aura and risk of cardiovascular and all cause mortality in men and women: prospective cohort study.

Migraine with aura and risk of cardiovascular and all cause mortality in men and women: prospective cohort study. OBJECTIVE: To estimate whether migraine in mid-life is associated with mortality from cardiovascular disease, other causes, and all causes. DESIGN: Population based cohort study. SETTING: Reykjavik, Iceland. PARTICIPANTS: 18,725 men and women, born 1907-35 and living in Reykjavik and adjacent communities. MAIN OUTCOME MEASURES: Mortality from cardiovascular disease, non (...) -cardiovascular disease, and all causes. Questionnaires and clinical measures were obtained in mid-life (mean age 53, range 33-81) in the Reykjavik Study (1967-91). Headache was classified as migraine without aura, migraine with aura, or non-migraine headache. Median follow-up was 25.9 years (0.1-40.2 years), with 470,990 person years and 10,358 deaths: 4323 from cardiovascular disease and 6035 from other causes. We used Cox regression to estimate risk of death in those with migraine compared with others

BMJ2010 Full Text: Link to full Text with Trip Pro

159. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program

OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program 20487038 2010 07 12 2010 10 08 2011 06 13 1526-4610 50 6 2010 Jun Headache Headache OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. 921-36 10.1111/j.1526-4610.2010.01678.x To assess the efficacy, safety, and tolerability (...) of onabotulinumtoxinA (BOTOX) as headache prophylaxis in adults with chronic migraine. Chronic migraine is a prevalent, disabling, and undertreated neurological disorder. Few preventive treatments have been investigated and none is specifically indicated for chronic migraine. The 2 multicenter, pivotal trials in the PREEMPT: Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy clinical program each included a 24-week randomized, double-blind phase followed by a 32-week open-label phase (ClinicalTrials.gov

EvidenceUpdates2010

160. Prophylaxis of migraine headache

Prophylaxis of migraine headache 20159899 2010 04 20 2010 09 16 2017 02 20 1488-2329 182 7 2010 Apr 20 CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne CMAJ Prophylaxis of migraine headache. E269-76 10.1503/cmaj.081657 Pringsheim Tamara T Department of Clinical Neurosciences, University of Calgary, Calgary Headache Assessment and Management Program, Foothills Medical Centre, 1403-29th St. NW, Calgary AB T2N 2T9. tmprings@ucalgary.ca Davenport W Jeptha (...) . 2007 Jan 30;68(5):343-9 17261680 Headache. 1990 Nov;30(11):710-5 2074163 Neurol Sci. 2004 Dec;25(5):245-50 15624081 Phytomedicine. 1996 Nov;3(3):225-30 23195074 JAMA. 1983 Nov 11;250(18):2500-2 6355533 Clin Ter. 2000 May-Jun;151(3):145-8 10958046 Cephalalgia. 2006 May;26(5):578-88 16674767 Anticonvulsants therapeutic use Antidepressive Agents therapeutic use Antihypertensive Agents therapeutic use Botulinum Toxins, Type A therapeutic use Decision Making Flunarizine therapeutic use Humans Migraine

EvidenceUpdates2010 Full Text: Link to full Text with Trip Pro